Overview
OrganaBio is a Miami-based CTDMO founded in 2018, providing high-quality cell and gene therapy starting materials like leukopaks, PBMCs, and donor tissues from ethically sourced birth tissue and peripheral blood. It offers clinical cell processing, rapid PBMC isolation, cryopreservation, analytical testing, and autologous apheresis services from facilities in Miami, FL, and Irvine, CA. These vertically integrated solutions support CAR-T, gene therapy, and advanced immunotherapy programs from research to clinical trials.
Frequently asked questions
- What cell therapy starting materials does OrganaBio supply?
- OrganaBio supplies donor-derived materials including leukopaks, PBMCs, immune cell products, and tissue-derived products from ethically sourced birth tissue and peripheral blood, available in research and GMP grades.
- What are OrganaBio's clinical processing capabilities?
- Capabilities include rapid PBMC isolation from whole blood, cryopreservation, analytical testing (cell enumeration, viability, immunophenotyping, stability, endotoxin), autologous apheresis, and cold storage for clinical trial samples.
- Where are OrganaBio's facilities located?
- OrganaBio operates facilities in Miami, FL (headquarters), and Irvine, CA, supporting U.S.-wide clinical trials with East and West Coast coverage.